VivoSim Labs, Inc. Common Stock

VIVS XNAS • BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

3.7M

Short interest (May 15)

1.4%

Net Short (Jun 03 ): 0.0%

Borrow Fee

342.31%

↓ 12.2%

Available Shares

30K

↓ 66.0%

Price Chart

Company Overview

VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.

Company Info

Exchange: NASDAQ

Industry: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

CIK: 0001497253

Asset Type: CS

Market Data

Market Cap: $3,704,984

Employees: 9

Status: Active

Short Interest

Current Borrow Fee 342.31%

Range: 342.31% - 352.44%

Available Shares 30K

Range: 20K - 25K

Recent Changes

Fee Change: ↓ 1.3%

Available Change: ↑ 12.5%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime